skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Refine Results

Clear All


Show More


Show More

Show More


Show More

Show More

15 Total results for product and free and sample content found


Discover the top medtech stories from the last week below

By Chris Farrell 25 Sep 2017

Meddevicetracker weekly round up  

Topic Medtech weekly roundup

Medtech Insight

View Of The IVD Horizon: How Roche Diagnostics Sees The Sector Evolving

By Tina Tan 18 Apr 2017

While the in vitro diagnostics landscape has seen players come and go, Roche Diagnostics has remained at the top. But the Swiss giant, like all its other smaller rivals, is facing a new reality, with increasing pressures to prove medical value, and a more stringent regulatory environment. Medtech Insight spoke to Roche Diagnostics' Jean-Claude Gottraux, head of centralized and point of care solutions, and Jean-Jacques Palombo, lifecycle leader for the company's cardiac, women's health and personalized health care solutions immunoassay portfolio, to gain their perspectives on how the sector has evolved and will continue to evolve. They also spoke about the company's strategy to address these changes and challenges.

Pink Sheet

Just Trust Me: Most Firms Unwilling To Publicly Pledge Pricing Restraint

By Cathy Kelly 18 Apr 2017

Public Citizen reached out to the 28 largest biopharma manufacturers after Allergan announced its pricing pledge to see who else might follow suit. The answer was, not many.

Pink Sheet

A Hiring Freeze By A Different Name: OMB Wants Agency 'Workforce Reduction' Plans

By Derrick Gingery 18 Apr 2017

Latest Office of Management and Budget directive lifts the pause on federal hiring, but requires US FDA and others to develop long-term plans to cut staff.

Topic BioPharmaceutical FDA


ALEX Ups The Ante For Alecensa In ALK+ NSCLC

By Alex Shimmings 11 Apr 2017

Roche's Alecensa has bested Pfizer's Xalkori in the Phase III head-to-head ALEX study in first-line non-small-cell lung cancer, making a strong case for it to be the new gold standard therapy in ALK-positive patients, in favor of Novartis's Zykadia.

Topic Clinical trials Research Company analysis

Pink Sheet

Biogen CMO Notes iPhone's Potential For Early Detection of Alzheimer's

By Sten Stovall 05 Apr 2017

Biogen's chief medical officer says iPhone technology should in future be used for early warning diagnosis of Alzheimer's Disease.

Topic Alzheimers

Pink Sheet

A Look At Payers' Early Game Plans For Driving Biosimilar Use

By Emily Hayes 05 Apr 2017

Interviews with US payers suggest that at first they are more likely to focus on promoting biosimilars in treatment-naïve patients, as opposed to switching those on branded drugs, according to a new Datamonitor report.

Topic Biosimilars

Pink Sheet

Running The Drug Catalyst Gauntlet: What To Look For In Q2 2017

By Sten Stovall 05 Apr 2017

Neurotrope's novel bryostatin treatment for Alzheimer's, AstraZeneca's durvalumab in bladder cancer, and Actelion’s antibiotic cadazolid are among a raft of therapies scheduled for major data read-outs or approval decisions in Q2 2017. With the help of Informa Pharma Intelligence’s Biomedtracker, Scrip takes a look at some crucial drug displays likely over the next three months.

Topic Alzheimers Cancer Clinical trials

Pink Sheet

User Fee Bill Could Become Ensnared In US Abortion Politics

By Derrick Gingery 31 Mar 2017

Amendment defunding Planned Parenthood is one ACA repeal refugee that could hitch a ride with user fee bill, which would be 'problematic,' to say the least, for Democrats.

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: